Current antiarrhythmic drug therapy in atrial fibrillation;Möglichkeiten und Grenzen der Derzeitigen Medikamentösen Behandlung von Vorhofflimmern

Deutsche Medizinische Wochenschrift

Volumn 135, Issue SUPPL. 2, 2010, Pages

  Goette, A ^a  

^a St Vincenz Hospital   (Germany)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Pathophysiology; Pharmacology; Therapy

Indexed keywords

ANGIOTENSIN II; ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE;

CLINICAL FEATURE; DRUG INDICATION; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HUMAN; MONOTHERAPY; PROPHYLAXIS; REVIEW;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 77949365771     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1249206     Document Type: Review

References (32)

1. Alboni P, Botto G L., Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the pill-in-the-pocket approach. N Engl J Med 2004 351 2384-2391
2. Benjamin E J., Dagostino R B., Belanger A J. et al. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995 92 835-841
3. Davy J M., Herold M, Hoglund C et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008 156 527 e1-9
4. Dobrev D, Ravens U. Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol 2003 98 137-148
5. Ehrlich J R., Hohnloser S H., Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006 27 512-518
6. Fuster V, Ryden L E., Cannom D S. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 114 e257-354
7. Disertori M, Latini R, et al, GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009 360 1606-1617
8. Goette A, Bukowska A, Lendeckel U et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008 117 732-742
9. Goette A, Staack T, Arndt M et al. Increased expression of extracellular-signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000 35 1669-1677
10. Goette A, Lendeckel U. Non-channel drug targets in atrial fibrillation. Pharmacol Therap 2004 102 17-36
11. Gramley F, Himmrich E, Mollnau H et al. Recent advances in the pharmacological treatment of cardiac arrythmias. Drugs Today (Barc) 2009 45 807-824
12. Hammwöhner M, Smid J, Lendeckel U, Goette A. New drugs for atrial fibrillation. J Interv Card Electrophysiol 2008 23 15-21
13. Healey J S., Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005 45 1832-1839
14. Lewalter T, Lderitz B. Arzneimitteltherapie der Herzrhythmusstö rungen. Internist 2000 41 S22-S33
15. Kannel W B., Abbott R D., Savage D D., McNamara P M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982 306 1018-1022
16. Krahn A D., Manfreda J, Tate R B. et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba follow-up study. Am J Med 1995 98 476-484
17. Khlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck O A. Use of metoprolol cr/xl to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol 2000 36 139-146
18. Lafuente-Lafuente C, Mouly S, Longas-Tejero M A., Bergmann J F. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007 CD005049
19. Lafuente-Lafuente C, Mouly S, Longas-Tejero M A. et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006 166 719-728
20. Lee S H., Chen S A., Chiang C E. et al. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med 1996 239 253-260
21. Li D, Fareh S, Leung T K., Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999 100 87-95
22. Lip G YH, Beevers D G. History, epidemiology and importance of atrial fibrillation. Br Med J 1995 311 1361-1363
23. Meinertz T, Lip G Y., Lombardi F et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002 90 1300-1306
24. Nattel S, Li D, Yue L. Basic mechanisms of atrial fibrillation very new insights into old ideas. Ann Rev Physiol 2000 62 51-77
25. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002 415 219-226
26. Touboul P, Brugada J, Capucci A et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003 24 1481-1487
27. Singh B N., Connolly S J., Crijns H J. et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007 357 987-999
28. Torp-Pedersen C, Moller M, Bloch-Thomsen P E. et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999 341 857-865
29. Wyse D G., Waldo A L., DiMarco J P. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 1825-1833
30. Zellerhoff S, Goette A, Kirchhof P. Antikoagulation bei Vorhofflimmern. Herzschrittmacherther Elektrophysiol 2006 17 89-94
31. Ahmed S, Rienstra M, Crijns H J. et al. Continous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008 300 1784-1792
32. Hohnloser S H., Crijns H JGM, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009 360 668-678